

Rize Oncology Inc. Announces Intention to Seek Shareholder Approval for Voluntary Delisting from the Canadian Securities Exchange

Kelowna, British Columbia – April 22, 2025 – Rize Oncology Inc. (CSE: RIZE) (“Rize” or the “Company”), a clinical-stage pharmaceutical company focused on developing innovative oncology therapeutics, today announced that its Board of Directors has authorized the Company to seek shareholder approval for the voluntary delisting of its common shares from the Canadian Securities Exchange (“CSE”).

The proposed delisting is subject to the approval of a majority of the Company’s shareholders, excluding votes cast by “Related Persons” (as defined in CSE Policy 1), and final approval by the CSE. In accordance with CSE Policies, Rize anticipates seeking the requisite shareholder approval via written resolution signed by holders of more than 50% of the common shares eligible to vote on the resolution. If such approvals are obtained, Rize intends to proceed with the delisting of its common shares from the CSE within two weeks following the receipt of the approvals. Subsequent to delisting, the Company will continue to be a reporting issuer in certain jurisdictions in Canada and will remain subject to continuous disclosure requirements. All shareholders as of the date of delisting will remain shareholders of the Company.

“With the in-licensing of STS-201, our Board of Directors has determined that the current market capitalization and trading activity on the Canadian Securities Exchange does not reflect the true value or long-term potential of Rize Oncology,” said Daren Graham, Executive Chairperson. “Given current market conditions and our belief that the STS-201 development program is significantly undervalued, we believe our shareholders will be better served by removing our shares from the CSE as we advance the asset toward clinical development.”

About Rize Oncology Inc.

Rize Oncology Inc. is a clinical-stage biopharmaceutical company dedicated to the development of STS-201, a small-molecule drug with a unique mechanism of action, currently being evaluated for its potential in treating soft tissue sarcoma and other cancers.

Contact:

Roland Boivin, CEO
(833) 294-4363 ext. 1
roland@rizeoncology.com

Daren Graham, Executive Chairman
(833) 294-4363 ext. 2
daren@rizeoncology.com

Forward-Looking Statements

This news release contains statements that constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may

cause Rize's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur. Forward-looking statements in this document include the Company's expectation that it will seek disinterested shareholder approval for the delisting of the Company's common shares from the CSE and all other statements that are not statements of historical fact.

Although Rize believes the forward-looking information contained in this news release is reasonable based on information available on the date hereof, by their nature forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such statements.

Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with general economic conditions; adverse industry events; future legislative and regulatory developments; the Company's ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the ability of Rize to implement its business strategies; competition; the ability of Rize to obtain and retain all applicable regulatory and other approvals and other assumptions, risks and uncertainties that may be disclosed in the Company's continuous disclosure record from time to time.